产品资料

MedKoo Biosciences/L-2286/406368/5g

L-2286 is a novel PARP inhibitor. L-2286 exerted significant protective effect against ischemia-reperfusion-induced myocardial injury in both experimental models. More importantly, L-2286 facilitated the ischemia-reperfusion-induced activation of Akt, extracellular signal-regulated kinase, and p38-MAPK in both isolated hearts and in vivo cardiac injury.

MedKoo Cat#: 406368
Name: L-2286
CAS#: 684276-17-3
Chemical Formula: C15H19N3OS
Exact Mass: 289.12488
Molecular Weight: 289.39586
Elemental Analysis: C, 62.25; H, 6.62; N, 14.52; O, 5.53; S, 11.08

Synonym: L2286; L 2286; L-2286.

IUPAC/Chemical Name: 2-((2-(piperidin-1-yl)ethyl)thio)quinazolin-4(3H)-one

InChi Key: QEAAIHDHSHTGMZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H19N3OS/c19-14-12-6-2-3-7-13(12)16-15(17-14)20-11-10-18-8-4-1-5-9-18/h2-3,6-7H,1,4-5,8-11H2,(H,16,17,19)

SMILES Code: O=C1NC(SCCN2CCCCC2)=NC3=C1C=CC=C3

Technical Data

Appearance:

white solid powder

Purity:

>98% (or refer to the Certificate of Analysis)

Shipping Condition:

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:

Soluble in DMSO, not in water

Shelf Life:

>2 years if stored properly

Drug Formulation:

This drug may be formulated in DMSO

Stock Solution Storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

293490

Additional Information

References

1: Bartha E, Solti I, Szabo A, Olah G, Magyar K, Szabados E, Kalai T, Hideg K, Toth K, Gero D, Szabo C, Sumegi B, Halmosi R. Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure. J Cardiovasc Pharmacol. 2011 Oct;58(4):380-91. doi: 10.1097/FJC.0b013e318225c21e. PubMed PMID: 21697725.

2: KÃ¶vesdi E, Bukovics P, Besson V, NyirÃ¡di J, LÃ¼ckl J, PÃ¡l J, SÃ¼megi B, DÃ³czi T, HernÃ¡di I, BÃ¼ki A. A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study. Int J Mol Sci. 2010 Mar 26;11(4):1253-68. doi: 10.3390/ijms11041253. PubMed PMID: 20480019; PubMed Central PMCID: PMC2871115.

3: Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, KÃ¡lai T, Hideg K, Halmosi R, Sumegi B, Toth K. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res. 2009 Aug 1;83(3):501-10. doi: 10.1093/cvr/cvp144. Epub 2009 May 14. PubMed PMID: 19443425.

4: Bartha E, Kiss GN, Kalman E, KulcsÃ¡r G, KÃ¡lai T, Hideg K, Habon T, Sumegi B, Toth K, Halmosi R. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J Cardiovasc Pharmacol. 2008 Sep;52(3):253-61. doi: 10.1097/FJC.0b013e3181855cef. PubMed PMID: 18806606.

5: Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, Kulcsar G, Kalai T, Hideg K, Gallyas F Jr, Sumegi B, Toth K, Halmosi R. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J Mol Cell Cardiol. 2006 Jul;41(1):149-59. Epub 2006 May 23. PubMed PMID: 16716347.

6: PÃ¡lfi A, TÃ³th A, KulcsÃ¡r G, HantÃ³ K, Deres P, Bartha E, Halmosi R, Szabados E, Czopf L, KÃ¡lai T, Hideg K, SÃ¼megi B, TÃ³th K. The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts. J Pharmacol Exp Ther. 2005 Oct;315(1):273-82. Epub 2005 Jun 10. PubMed PMID: 15951400.

对照品标准品，生物试剂盒，gibco胎牛血清，试剂采购网，中国试剂网，细胞因子试剂盒

MedKoo Biosciences/L-2286/406368/5g

Technical Data

Additional Information

References